The vascular endothelium serves as a critical barrier preventing the transmigration of monocytes, circulating lipoproteins, and other molecules into the subendothelial space, and plays a vital role in regulating vascular tone. A dysfunctional and inflamed endothelial layer in response to disturbed blood flow or other proatherogenic risk factors is the initiating event in the pathogenesis of atherosclerosis, suggesting the importance of an intact and properly functioning endothelium in preventing the onset and progression of this disease. Accumulated evidence demonstrates the significant role of matricellular proteins, which are non-structural and secretory extracellular matrix (ECM) proteins, in the development of atherosclerosis. These proteins exert multifaceted effects on endothelial cells (ECs) ranging from reactive oxygen species (ROS) production, endoplasmic reticulum stress, and expression of adhesion molecules to autophagy and compromised barrier function via stimulating various molecular mechanisms. Given the critical roles of these processes in EC function and atherosclerosis, a better understanding of signaling pathways governed by matricellular proteins in ECs is required to develop therapeutic strategies for suppressing or preventing atherosclerosis and related cardiovascular diseases (CVDs). This review comprehensively summarizes the existing literature on the diverse roles of matricellular proteins in regulating EC inflammation and function, and highlights their potential as viable therapeutic targets for maintaining vascular health and inhibiting the progression of atherosclerosis.
Clinical and genetic studies strongly support a significant connection between nonalcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular disease (ASCVD) and identify ASCVD as the primary cause of death in NAFLD patients. Understanding the molecular factors and mechanisms regulating these diseases is critical for developing novel therapies that target them simultaneously. Our preliminary immunoblotting experiments demonstrated elevated expression of nidogen 2 (NID2), a basement membrane glycoprotein, in human atherosclerotic vascular tissues and murine steatotic livers. Therefore, we investigated the role of NID2 in regulating hepatosteatosis and atherosclerosis utilizing Western diet-fed Apoe−/− mice with/without NID2 overexpression. Quantitative real-time PCR confirmed increased NID2 mRNA expression in multiple organs (liver, heart, kidney, and adipose) of NID2-overexpressing mice. Male mice with NID2 overexpression exhibited higher liver and epididymal white adipose tissue mass, increased hepatic lipid accumulation, and fibrosis. Additionally, these mice developed larger atherosclerotic lesions in the whole aortas and aortic roots, with increased necrotic core formation. Mechanistic studies showed reduced AMPK activation in the livers of NID2-overexpressing mice compared with controls, without any effects on hepatic inflammation. In conclusion, these findings suggest that NID2 plays a deleterious role in both hepatosteatosis and atherosclerosis, making it a potential therapeutic target for these conditions.
The clinical and genetic studies strongly support a significant connection between nonalcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular disease (ASCVD) and identify ASCVD as the primary cause of death in NAFLD patients. Understanding the molecular factors and mechanisms regulating these diseases, is critical for developing novel therapies that target them simultaneously. Our preliminary immunoblotting experiments demonstrated elevated expression of nidogen 2 (NID2), a basement membrane glycoprotein, in human atherosclerotic vascular tissues and murine steatotic livers. Therefore, we investigated the role of NID2 in regulating hepatosteatosis and atherosclerosis utilizing Western diet-fed Apoe-/- mice with/without NID2 overexpression. Quantitative real-time PCR confirmed increased NID2 mRNA expression in multiple organs (liver, heart, kidney and adipose) of NID2-overexpressing mice. Male mice with NID2 overexpression exhibited higher liver and epididymal white adipose tissue mass, increased hepatic lipid accumulation and fibrosis. Additionally, these mice developed larger atherosclerotic lesions in the whole aortas and aortic roots, with increased necrotic core formation. Mechanistic studies showed reduced AMPK activation in the livers of NID2-overexpressing mice compared with controls, without any effects on hepatic inflammation. In conclusion, these findings suggest that NID2 plays a deleterious role in both hepatosteatosis and atherosclerosis, making it a potential therapeutic target for these conditions.
Metabolic dysfunction-associated steatotic liver disease (MASLD) primarily results from dysregulated lipid metabolism in hepatocytes. However, the mechanisms governing hepatic lipid metabolism remain incompletely understood. Our preliminary experiments demonstrated elevated expression of R-spondin 2 (RSPO2), a matricellular protein, in steatotic livers. Therefore, we investigated the role of RSPO2 in MASLD and potential underlying mechanisms. Comprehensive in vivo and in vitro studies were performed to investigate the role of RSPO2 in steatosis. Unbiased transcriptomic analyses of hepatic RNA samples were conducted to identify RSPO2-regulated signaling pathways. To examine the in vivo role of Rspo2, both hepatocyte-specific Rspo2-deficient mice and AAV-mediated Rspo2 overexpression were utilized. RSPO2 expression was significantly increased in steatotic livers of high-fat diet-fed wild-type (p <0.01) and Western diet-fed Apoe-/- mice (p <0.001). Similar results were observed with human steatotic liver tissues (p <0.01). Hepatocyte-specific deletion of Rspo2 in floxed mice, achieved either via postnatal TBG-Cre-AAV injection or embryonic Alb-Cre breeding, exacerbated diet-induced hepatic steatosis and fibrosis, suggesting that RSPO2 has protective effects against MASLD. Conversely, AAV-mediated Rspo2 overexpression in mice reduced hepatic lipid deposition (p <0.01) and decreased hepatic triglyceride and non-esterified fatty acid levels after high-rich diet feeding. Furthermore, Rspo2 overexpression suppressed hepatic fibrosis (p <0.01) and macrophage accumulation. Mechanistic studies using RNA sequencing and other techniques revealed improved lipid metabolism, increased AMPK-ACC signaling, reduced inflammation, and attenuated apoptosis in the liver with Rspo2 overexpression. In vitro experiments further demonstrated the anti-steatotic effects of recombinant RSPO2 treatment in hepatocytes. These findings identify RSPO2 as a key suppressor of hepatic steatosis and fibrosis, and highlight its potential as a therapeutic target for MASLD. Given the hepatic/extrahepatic complications associated with MASLD (metabolic dysfunction-associated steatotic liver disease) and its high prevalence, it is crucial to decipher the precise molecular mechanisms regulating its pathogenesis to identify novel druggable targets. In this study, we demonstrate for the first time that hepatocyte RSPO2 plays a protective role against hepatic steatosis, fibrosis, and inflammation. Rspo2 overexpression improves lipid metabolism, enhances AMPK-ACC signaling, and reduces hepatocyte apoptosis. Therefore, targeting RSPO2 in hepatocytes may represent a promising strategy to suppress MASLD.
2 July 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
BACKGROUND: Monocyte-derived macrophages play a significant role in the initiation and progression of atherosclerosis by transforming into lipid-laden foam cells and regulating vascular inflammation. However, the molecular mechanisms that regulate macrophage lipid accumulation, phenotype, efferocytic capacity, and atherosclerosis are incompletely understood. Our preliminary studies revealed increased expression of LGR4 (leucine-rich repeat-containing G protein-coupled receptor 4) in human atherosclerotic arteries. Additional experiments demonstrated increased LGR4 levels in atherogenic oxidized low-density lipoprotein–treated macrophages. However, the macrophage-specific role of LGR4 in atherogenesis has never been investigated. METHODS: To investigate the role of myeloid cell Lgr4 in atherosclerosis development, myeloid cell-specific Lgr4 knockout ( Lgr4f/fLysM Cre ± , Lgr4ΔM ) and littermate control Lgr4f/f ( Lgr4WT ) mice were injected intraperitoneally with h PCSK9 -AAV8 and fed a Western diet for 16 weeks. Various in vitro cell-based assays, molecular biology techniques, and immunohistological approaches were used to evaluate the functional roles of macrophage Lgr4 and underlying signaling mechanisms. RESULTS: Oil red O staining of whole aortas and aortic root sections demonstrated reduced atherosclerosis in Lgr4ΔM mice compared with sex-matched Lgr4WT mice. However, no changes in circulating monocyte frequencies were detected. Histochemical staining performed on aortic root sections revealed smaller necrotic cores and higher collagen content in Lgr4ΔM mice. Additionally, Lgr4ΔM mice exhibited lower fat mass and blood glucose levels, while plasma total cholesterol was comparable to that of control mice. Further in vitro and ex vivo studies demonstrated reduced lipid accumulation, enhanced efferocytic capacity, a suppressed proinflammatory phenotype, and attenuated expression of different low-density lipoprotein uptake genes in Lgr4 -deficient macrophages. Moreover, Lgr4 knockout macrophages displayed increased cholesterol efflux capacity and reduced activation of oxidized low-density lipoprotein–induced Wnt/β-catenin signaling. CONCLUSIONS: These findings suggest that myeloid cell Lgr4 contributes to atherosclerotic lesion formation via stimulating macrophage lipid accumulation, impairing efferocytic capacity, and promoting a proinflammatory phenotype. Collectively, these results identify macrophage LGR4 as a novel therapeutic target for atherosclerosis.